Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women’s health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro
| Current Price | ₹2,249.55 |
|---|---|
| Market Cap | ₹1,02,853 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 19.3 |
| Return on Equity | 26.91% |
| 52-Week Range | ₹1,836.80 – ₹2,494.00 |
| Beta (1Y) | 0.42 |
| Dividend Yield | 0.80% |
1. Pharmaceuticals-99.5% 2. Others-0.5%
Lupin Ltd is trading at ₹2,249.55, with a market capitalisation of ₹1,02,853 Cr.
Lupin Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Lupin Ltd has a P/E of 19.3 and a return on equity of 26.91%.